European IVD Directive draft includes "common technical specifications" for highest-risk tests.
This article was originally published in The Gray Sheet
Executive Summary
IVD "COMMON TECHNICAL SPECIFICATIONS" ADDED TO EUROPEAN DIRECTIVE for blood grouping and retroviral tests. Under the latest draft of the European Union directive for in vitro diagnostics, manufacturers of designated high-risk tests could no longer bring the products to market simply by meeting quality systems requirements; they would also have to submit a design dossier for review by a notified body showing compliance with the common technical specifications.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.
Maxwellia Delivers Two UK Menstrual Health Rx-To-OTC Switches
UK switch specialist Maxwellia delivers two “me too” reclassifications in the area of women's health: Evana Heavy Period Relief and Ultravana Period Pain Relief.